Eileen Shiuan
Researcher Next ID · RN-031574
Researcher · Chemical Engineering
University of California, Los Angeles
Los Angeles, United States
- Works count
- 2,530
- Citation count
- 744
- H-index
- 10
- i10-index
- 11
Research interests
Publications
Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors
Journal of Clinical Investigation · 2023 · 10.1172/jci169314
Oncogenic functions and therapeutic targeting of EphA2 in cancer
Oncogene · 2021 · 10.1038/s41388-021-01714-8
Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma
Cancers · 2021 · 10.3390/cancers13061475
Host deficiency in ephrin-A1 inhibits breast cancer metastasis
F1000Research · 2020 · 10.12688/f1000research.22689.1
Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity
JCI Insight · 2020 · 10.1172/jci.insight.139237
Host deficiency in ephrin-A1 inhibits breast cancer metastasis
F1000Research · 2020 · 10.12688/f1000research.22689.2
Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes
Journal of Thoracic Oncology · 2019 · 10.1016/j.jtho.2019.05.042
The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ
Science Signaling · 2017 · 10.1126/scisignal.aan4667
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Journal for ImmunoTherapy of Cancer · 2017 · 10.1186/s40425-017-0210-0
Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
Clinical and Translational Science · 2016 · 10.1111/cts.12408
Eph Receptor Tyrosine Kinases in Tumor Immunity
Cancer Research · 2016 · 10.1158/0008-5472.can-16-1521
Current projects
No projects listed.